Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Join The Club: Alnylam Signs On Takeda In RNAi Platform Deal

This article was originally published in The Pink Sheet Daily

Executive Summary

Takeda gains non-exclusive access to Alnylam’s RNAi therapeutics platform in oncology and metabolic disease for $150 million upfront.

You may also be interested in...



Alnylam CEO John Maraganore - An Interview With "The Pink Sheet" DAILY (Part 1 of 2)

CEO of the RNAI pioneer firm talks about life after the Roche collaboration and how its partnership with Takeda is different.

Alnylam CEO John Maraganore - An Interview With "The Pink Sheet" DAILY (Part 1 of 2)

CEO of the RNAI pioneer firm talks about life after the Roche collaboration and how its partnership with Takeda is different.

Alnylam/Takeda RNAi collaboration selected as “Deal of the Year”

Last May's agreement between Alnylam and Takeda on a non-exclusive RNA interference platform collaboration focused on oncology and metabolic disease wins in In Vivo Blog's first annual "Deals of the Year" competition. Out of 13 deal candidates, the Alnylam/Takeda tie-up led the voting from start to finish, garnering 35 percent of the votes. The collaboration brought Alnylam $150 million upfront, allowing it to finish the year with about $500 million in cash without restricting its own business prospects or diluting its stock, while also making Takeda Japan's only major player in the RNAi space (1"The Pink Sheet" DAILY, May 27, 2008). In an acceptance speech posted at In Vivo Blog, Alnylam thanked many, including "small molecules and antibodies for giving us undruggable targets" (2In Vivo Blog, Jan. 7, 2009)

Related Content

Topics

UsernamePublicRestriction

Register

OM006764

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel